Reuters: Regulatory News: Medicis' skin drug gets generic threat from Actavis Mid Atlantic

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Medicis' skin drug gets generic threat from Actavis Mid Atlantic Aug 15th 2012, 11:47 Wed Aug 15, 2012 7:47am EDT Aug 15 (Reuters) - Medicis Pharmaceutical Corp said generic drugmaker Actavis Mid Atlantic filed a marketing application for a generic version of one of Medicis' skin drugs. The drug Zyclara is used to treat patients with actinic keratosis, a small, red, raised area on the skin that has been exposed to the sun for a long time. Zyclara is currently protected by two patents, one of which is valid until 2029. The cream's seven-year marketing exclusivity will expire in March 2013. Medicis said it will defend its intellectual property rights relating to the product. Zyclara is one of the company's key non-acne dermatology products. The Scottsdale, Arizona-based Medicis acquired Zyclara through its purchase of the bankrupt drugmaker Graceway Pharmaceutical LLC for $455 million in November. Medicis, which focuses primarily on the treatment of dermatological conditions, has a market value of $1.93 billion as of Tuesday's close.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions